HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Addition of albumin to Traditional Risk Score Improved Prediction of Mortality in Individuals Undergoing Transcatheter Aortic Valve Replacement.

AbstractOBJECTIVES:
The ability of the Society of Thoracic Surgeons (STS) and European System for Cardiac Operative Risk Evaluation (EuroSCORE)-2 scores to predict outcomes after transcatheter aortic valve replacement (TAVR) is insufficient. Frailty and serum albumin as a frailty marker were shown to correlate with prognosis after TAVR. We sought to evaluate the additive value of serum albumin to STS and EuroSCORE-2 scores to predict mortality in individuals undergoing TAVR.
DESIGN:
Retrospective analysis.
SETTING:
Tertiary-care hospital prospective registry.
PARTICIPANTS:
Individuals who underwent TAVR (N = 426).
MEASUREMENTS:
We compared survival rates according to median baseline albumin levels (4 g/dL), STS score (4.5%), and EuroSCORE-2 (3.45%). Participants were divided into four groups according to median serum albumin and median STS and EuroSCORE-2 scores (high vs low), and 1-year survival rates were compared. A category-free net reclassification index (NRI) was calculated to compare the ability of a model of STS or EuroSCORE-2 alone to classify mortality risk with and without the addition of baseline serum albumin.
RESULTS:
Participants with low albumin levels had higher mortality (hazard ratio (HR) = 3.03, 95% confidence interval (CI) = 1.66-5.26, P < .001). Participants with low serum albumin and a high STS (HR = 4.55, 95% CI = 2.21-9.38, P < .001) or EuroSCORE-2 (HR = 2.72, 95% CI = 1.48-5.06, P = .001) score had higher mortality. Using NRI analysis, a model that included albumin in addition to STS correctly reclassified 42% of events (NRI = 0.58) and a model that included albumin in addition to EuroSCORE-2 correctly reclassified 44% of events (NRI = 0.64).
CONCLUSION:
Serum albumin, as a marker of frailty, can significantly improve the ability of STS and EuroSCORE-2 scores to predict TAVR-related mortality.
AuthorsYoni Grossman, Israel M Barbash, Paul Fefer, Ilan Goldenberg, Anat Berkovitch, Ehud Regev, Noam Fink, Sagit Ben-Zekry, Yafim Brodov, Alexander Kogan, Victor Guetta, Ehud Raanani, Amit Segev
JournalJournal of the American Geriatrics Society (J Am Geriatr Soc) Vol. 65 Issue 11 Pg. 2413-2417 (Nov 2017) ISSN: 1532-5415 [Electronic] United States
PMID28941287 (Publication Type: Journal Article)
Copyright© 2017, Copyright the Authors Journal compilation © 2017, The American Geriatrics Society.
Topics
  • Aged
  • Aged, 80 and over
  • Cause of Death
  • Europe
  • Female
  • Heart Valve Prosthesis (statistics & numerical data)
  • Heart Valve Prosthesis Implantation (mortality)
  • Hospital Mortality
  • Humans
  • Male
  • Prognosis
  • Propensity Score
  • Retrospective Studies
  • Risk Factors
  • Severity of Illness Index
  • Survival Rate (trends)
  • Transcatheter Aortic Valve Replacement (mortality)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: